Interpharma members currently invest around CHF 6.5 billion a year in research and development in Switzerland.
are numerous diseases that often used to prove serious or fatal for patients, for example hepatitis C, thanks to innovative medicines.
Pharmacological and technological innovations will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research.
People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
show more articles
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2024
read more
Introducing Interpharma
read more
More about the tasks and overriding aims of Interpharma
read more
Contact us
read more
Latest information and media contacts for media representatives
read more
Download